2.Tiantian Zuo, Tianxu Fang, Jun Zhang, Jie Yang, Rui Xu, Zhihua Wang, Huizi Deng, Qi Shen. (2021) pH-Sensitive Molecular-Switch-Containing Polymer Nanoparticle for Breast Cancer Therapy with Ferritinophagy-Cascade Ferroptosis and Tumor Immune Activation. Advanced Healthcare Materials, 10 (21):(2100683). [PMID:34535975][10.1002/adhm.202100683]
3.Liangliang Dai,Xiang Li,Mengjiao Yao,Peiyun Niu,Xichen Yuan,Ke Li,Maowen Chen,Zengxiang Fu,Xianglong Duan,Haibin Liu,Kaiyong Cai,Hui Yang. (2020-02-29) Programmable prodrug micelle with size-shrinkage and charge-reversal for chemotherapy-improved IDO immunotherapy.. Biomaterials, 241 (119901-119901). [PMID:32109706]
References
1.Nayak-Kapoor A, Hao Z, Sadek R, Dobbins R, Marshall L, Vahanian NN, Jay Ramsey W, Kennedy E, Mautino MR, Link CJ et al.. (2018) Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors.. J Immunother Cancer, 6 (1):(61). [PMID:29921320][10.1021/op500134e]
2.Ma S, Suchomel J, Yanez E, Yost E, Liang X, Zhu R, Le H, Siebers N, Joas L, Morley R et al.. (2019) Investigation of the absolute bioavailability and human mass balance of navoximod, a novel IDO1 inhibitor.. Br J Clin Pharmacol, 85 (8):(1751-1760). [PMID:30973970][10.1021/op500134e]
3.Kumar S, Waldo JP, Jaipuri FA, Marcinowicz A, Van Allen C, Adams J, Kesharwani T, Zhang X, Metz R, Oh AJ et al.. (2019) Discovery of Clinical Candidate (1R,4r)-4-((R)-2-((S)-6-Fluoro-5H-imidazo[5,1-a]isoindol-5-yl)-1-hydroxyethyl)cyclohexan-1-ol (Navoximod), a Potent and Selective Inhibitor of Indoleamine 2,3-Dioxygenase 1.. J Med Chem, 62 (14):(6705-6733). [PMID:31264862][10.1021/op500134e]
L2215721